JP6446025B2 - 癌に対する薬剤併用療法のための化合物 - Google Patents

癌に対する薬剤併用療法のための化合物 Download PDF

Info

Publication number
JP6446025B2
JP6446025B2 JP2016501988A JP2016501988A JP6446025B2 JP 6446025 B2 JP6446025 B2 JP 6446025B2 JP 2016501988 A JP2016501988 A JP 2016501988A JP 2016501988 A JP2016501988 A JP 2016501988A JP 6446025 B2 JP6446025 B2 JP 6446025B2
Authority
JP
Japan
Prior art keywords
compound
cancer
therapeutic agent
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016501988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512563A5 (enExample
JP2016512563A (ja
Inventor
ストグニュー、マーティン
イー． アレン、ジョシュア
イー． アレン、ジョシュア
エス． ポトーフ、リチャード
エス． ポトーフ、リチャード
ラオ ナラガンチュ、バスカラ
ラオ ナラガンチュ、バスカラ
エル． オルソン、ゲイリー
エル． オルソン、ゲイリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoceutics Inc
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of JP2016512563A publication Critical patent/JP2016512563A/ja
Publication of JP2016512563A5 publication Critical patent/JP2016512563A5/ja
Application granted granted Critical
Publication of JP6446025B2 publication Critical patent/JP6446025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016501988A 2013-03-13 2014-03-13 癌に対する薬剤併用療法のための化合物 Active JP6446025B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361779828P 2013-03-13 2013-03-13
US61/779,828 2013-03-13
US201361904718P 2013-11-15 2013-11-15
US61/904,718 2013-11-15
PCT/US2014/025885 WO2014160130A1 (en) 2013-03-13 2014-03-13 Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018119005A Division JP2018184411A (ja) 2013-03-13 2018-06-22 癌に対する薬剤併用療法のための化合物

Publications (3)

Publication Number Publication Date
JP2016512563A JP2016512563A (ja) 2016-04-28
JP2016512563A5 JP2016512563A5 (enExample) 2017-04-13
JP6446025B2 true JP6446025B2 (ja) 2018-12-26

Family

ID=51527915

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016501988A Active JP6446025B2 (ja) 2013-03-13 2014-03-13 癌に対する薬剤併用療法のための化合物
JP2018119005A Pending JP2018184411A (ja) 2013-03-13 2018-06-22 癌に対する薬剤併用療法のための化合物
JP2020114024A Pending JP2020172510A (ja) 2013-03-13 2020-07-01 癌に対する薬剤併用療法のための化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018119005A Pending JP2018184411A (ja) 2013-03-13 2018-06-22 癌に対する薬剤併用療法のための化合物
JP2020114024A Pending JP2020172510A (ja) 2013-03-13 2020-07-01 癌に対する薬剤併用療法のための化合物

Country Status (26)

Country Link
US (1) US9265765B2 (enExample)
EP (2) EP2968294B1 (enExample)
JP (3) JP6446025B2 (enExample)
KR (2) KR20220123335A (enExample)
CN (2) CN119954807A (enExample)
AU (3) AU2014244117B2 (enExample)
BR (1) BR112015023256A2 (enExample)
CA (2) CA2905037C (enExample)
CY (1) CY1121735T1 (enExample)
DK (1) DK2968294T3 (enExample)
EA (1) EA037937B1 (enExample)
ES (1) ES2734568T3 (enExample)
HR (1) HRP20191181T1 (enExample)
HU (1) HUE044238T2 (enExample)
IL (2) IL241452B (enExample)
LT (1) LT2968294T (enExample)
ME (1) ME03470B (enExample)
MX (2) MX2015012636A (enExample)
NZ (2) NZ751509A (enExample)
PL (1) PL2968294T3 (enExample)
PT (1) PT2968294T (enExample)
RS (1) RS59013B1 (enExample)
SG (2) SG11201507247WA (enExample)
SI (1) SI2968294T1 (enExample)
SM (1) SMT201900384T1 (enExample)
WO (1) WO2014160130A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024059840A (ja) * 2013-11-15 2024-05-01 オンコシューティクス インコーポレイテッド ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67757B1 (sr) 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
KR20200029627A (ko) 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
HUE069651T2 (hu) * 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra
SMT202500087T1 (it) * 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
KR20170037260A (ko) 2015-09-25 2017-04-04 현대자동차주식회사 차량용 배터리 시스템 및 그 제어 방법
WO2017132661A2 (en) 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
KR20170110520A (ko) * 2016-03-23 2017-10-11 고려대학교 산학협력단 mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
US11091483B2 (en) * 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka
EP3565548A4 (en) * 2017-01-04 2020-10-14 The Board of Trustees of the Leland Stanford Junior University TARGET GENES IN MYC-INDUCED NEOPLASIA
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
IT201800004082A1 (it) * 2018-03-29 2019-09-29 Berlin Chemie Ag Composizioni farmaceutiche antitumorali per terapia combinata
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル － ゲル テクノロジーズ リミテッド Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療
WO2020147842A1 (zh) * 2019-01-18 2020-07-23 南京明德新药研发有限公司 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR20220107229A (ko) 2019-11-28 2022-08-02 인엑스메드 (난징) 컴퍼니 리미티드 암 치료에서 bi853520의 용도
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
KR20220137666A (ko) * 2020-02-05 2022-10-12 인엑스메드 (난징) 컴퍼니 리미티드 Bi853520과 화학요법 약물의 병용
WO2021195698A1 (en) 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
EP4684834A1 (de) 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
AU2009324464B2 (en) 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
RS67757B1 (sr) * 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024059840A (ja) * 2013-11-15 2024-05-01 オンコシューティクス インコーポレイテッド ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法
JP7870305B2 (ja) 2013-11-15 2026-06-04 オンコシューティクス インコーポレイテッド ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法

Also Published As

Publication number Publication date
MX2015012636A (es) 2017-02-06
EP2968294B1 (en) 2019-05-01
EA201591715A1 (ru) 2016-07-29
SMT201900384T1 (it) 2019-09-09
SG11201507247WA (en) 2015-10-29
ME03470B (me) 2020-01-20
PT2968294T (pt) 2019-07-19
US20140271540A1 (en) 2014-09-18
BR112015023256A2 (pt) 2017-07-18
CY1121735T1 (el) 2020-07-31
IL241452A0 (en) 2015-11-30
IL275623A (en) 2020-08-31
JP2020172510A (ja) 2020-10-22
AU2019201896A1 (en) 2019-04-11
KR20220123335A (ko) 2022-09-06
PL2968294T3 (pl) 2019-10-31
CA3204801A1 (en) 2014-10-02
AU2020233606A1 (en) 2020-10-01
HRP20191181T1 (hr) 2019-10-04
AU2014244117A1 (en) 2015-10-08
SI2968294T1 (sl) 2019-08-30
WO2014160130A1 (en) 2014-10-02
NZ711948A (en) 2020-02-28
EP2968294A1 (en) 2016-01-20
CN119954807A (zh) 2025-05-09
JP2018184411A (ja) 2018-11-22
RS59013B1 (sr) 2019-08-30
SG10201808496VA (en) 2018-10-30
IL241452B (en) 2020-07-30
CA2905037C (en) 2023-08-29
EP3572083A1 (en) 2019-11-27
MX2019013643A (es) 2020-02-03
US9265765B2 (en) 2016-02-23
CA2905037A1 (en) 2014-10-02
EA037937B1 (ru) 2021-06-09
NZ751509A (en) 2023-03-31
KR102438135B1 (ko) 2022-08-29
HUE044238T2 (hu) 2019-10-28
AU2014244117B2 (en) 2018-12-20
LT2968294T (lt) 2019-07-25
KR20150136602A (ko) 2015-12-07
JP2016512563A (ja) 2016-04-28
DK2968294T3 (da) 2019-07-15
ES2734568T3 (es) 2019-12-10
CN105530937A (zh) 2016-04-27
EP2968294A4 (en) 2016-10-19
HK1217653A1 (en) 2017-01-20
CA2905037E (en) 2014-10-02

Similar Documents

Publication Publication Date Title
US20240216379A1 (en) 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidaz0[1,2-a]pyrid0[3,4-e] pyrimidin-5 (1 h)-one, salts thereof and methods of using the same in combination therapy
KR102438135B1 (ko) 7-벤질-10-(2-메틸벤질)-2,6,7,8,9,10-헥사하이드로이미다조[1,2-a]피리도[4,3-d]피리미딘-5(3h)-온과의 조합 치료요법
AU2020200875B2 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
US9688679B2 (en) 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
KR20240005186A (ko) 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조 [1,2-a]피리도[3,4-e]피리미딘-5(1h)-온, 그것의 유사체, 및 그것의 염과 치료에서의 그것의 사용 방법
WO2015073072A1 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
EA053312B1 (ru) Соединение в виде дигидрохлоридной соли, представляющее собой противораковый терапевтический агент
HK1217653B (en) 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170306

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171004

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20171004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181130

R150 Certificate of patent or registration of utility model

Ref document number: 6446025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250